

Co-stimulation lowers the threshold for activation of naive T cells by bacterial superantigens

Eric Marsolle, Genevieve De Becker, Marlene Bakhaus¹, Kris Thielemans², Jacques Urbain, Maril Maser (ed.) & Jean-Luc Lee

¹Laboratoire de Physiologie Animale, Département de Biologie Moléculaire, Université Libre de Bruxelles, 12-344 Rhode-Saint-Genèse, Belgium

²Division of Hematology-Immunology, Mayo Clinic School of the Mayo University, Boston, 55-1000 Brussels, Belgium

Key words: antigen presentation, co-stimulation, dendritic cells, myelobacterial enterotoxins, superantigens, T cell activation

Abstract

Myelobacterial enterotoxins bind class II MHC molecules on antigen presenting cells (APC) and stimulate T cells expressing appropriate T_H gene products. Although the role of non-TCR associated co-stimulatory receptors during antigen-specific T cell activation has been clearly established, the involvement of co-stimulatory activity in T cell activation by superantigens has been the matter of controversy. In this report, we examine the role of co-stimulation provided by selected APC populations in the response to bacterial enterotoxins (myelobacterial enterotoxin A, myelobacterial enterotoxin B and toxic shock syndrome type 1). We demonstrate that the APC population able to activate naive T cells to IL-2 production is heterogeneous, comprising both adherent (presumably dendritic) and non-adherent (mostly B lympholytic) cells. By stimulating naive T cells in the presence of graded doses of superantigens, we have observed that half-maximal IL-2 production was achieved at lower doses of superantigens in the presence of dendritic cells. Similarly, addition of antibodies to CD28 or B7.1 transduced cell lines increased the sensitivity of naive T cells to lower doses of superantigens. These observations indicate therefore that superantigens can be presented to naive T cells by APC displaying distinct levels of co-stimulatory activity, although with different efficacy. Thus, naive T cells are sensitive to CD28-mediated co-stimulation during superantigen mediated responses but IL-2 production can be induced by high doses of superantigens in the presence of APC expressing weak co-stimulatory activity. These observations are compatible with the hypothesis that CD28-mediated signals participate in T cell activation by lowering T cell sensitivity to TCR signals.

Introduction

A growing list of proteins produced by bacteria, mycoplasmas and viruses has been shown to provide a variety of pathogenic effects, including septic shock, in both human and mouse models. The term superantigen was introduced to describe this group of microbial agents sharing several important features that distinguish them from conventional antigens (for review, see 1). Superantigens behave as functional agents able to simultaneously interact with the variable V β region of the TCR with little influence of the other TCR components and with a conserved domain of the class II MHC molecule (independently of the polymorphic residues

on the nature of the bound peptide). As a consequence, a given superantigen is able to interact with a large fraction (1–10%) of the T cell repertoire, causing massive T cell activation and systemic release of inflammatory cytokines in the circulation. In fact, there is compelling evidence that the toxicity of superantigens *in vivo* is due to an exaggerated host T cell response as indicated by the fact that cyclosporin A is able to block the development of lethal shock (2). Moreover, SCID mice, which are naturally resistant to superantigen-induced toxicity, acquire superantigen sensitivity upon T cell reconstitution (2). Thus, most of the biological effects of superantigens

Correspondence to: J. Lee.

Received 22 March 1994, accepted 11 November 1994

appear to be related to their ability to polyclonally activate subsets of T lymphocyte-expressing receptors by epitopes.

It has been recently demonstrated that activation of resting T cells initiated by engagement of the TCR with superantigenic ligand antigen-MHC [signal 1] requires additional signals delivered by the antigen-presenting cell (APC) [signal 2]. For mice, see 28, molecules belonging to the B7 family [B7-1 (B7-1), B7-2 (B7-2)] which interact with counter-receptors (CD28 and CTLA-4) are thought to represent one of the most potent co-stimulatory molecules for T cell activation, and APC also co-stimulate resting T cells, such as dendritic cells (DC) [27], both both shown to express high levels of CTLA-4-binding ligands [8]. DC are known to induce potent T cell responses to superantigens in a CD28-dependent manner, suggesting that a role for B7-related co-stimulatory molecules in the response to bacterial superantigens [18]. However, superantigen-dependent proliferation can be induced by resting B cells [29], known to express low levels of co-stimulatory activity. In another study, CD28-B7-independent stimulation of naive T cells by superantigens has been reported [30]. The conflicting results reported in the literature concerning the role of co-stimulation in the *in vivo* responses to superantigens may be due to superantigen doses and origin, host species, and experimental conditions. Direct pathogenicity of superantigens strongly correlates with their ability to activate naive T cells, and the nature of the cells presenting superantigens is strongly determining their toxicity *in vivo*.

In order to gain information on the role of APC and co-stimulation in the immune response to superantigens, we have performed a detailed analysis of the *in vitro* response of naive naive T cells to bacterial superantigens presented by distinct classes of presenting cell populations. Our data confirm that the ability to activate naive T cells *in vitro* is not restricted to a particular class of positive cell population, since both adherent and non-adherent cells contribute proliferation and IL-2 production in the presence of superantigens. Co-stimulatory activity (provided by surface CD80/86) is provided by dendritic cells (CD80-stimulatory) and is produced in response to superantigens in naive T cells. The comparative study of the *in vitro* response of naive T cells to several bacterial superantigens (staphylococcal enterotoxin A (SEA), staphylococcal enterotoxin B (SEB) and toxic shock syndrome toxin 1 (TSST-1)) known to display distinct affinities for murine MHC class II determinants also suggests that in vitro requirements for co-stimulatory activity are strongly dependent upon superantigen concentration and affinity. Overall, these observations suggest that co-stimulation provided by molecules of the B7 family increases T cells responsiveness to superantigens by lowering the threshold of TCR-dependent activation.

Materials

Mice

Female BALB/c mice, 6–8 weeks old, were purchased from Charles River Wiga (Sulzfeld, Germany).

Reagents

Hamster mAb 33.81 to murine CD28 and control mAb F591 kindly provided by J. Allison, University of California, Berkeley,

CA, USA were used at 100 000 dilution of ascitic fluids. The mAb anti-SEB to mouse B7-1 (F5) was kindly provided by M. Matsuda (Hiroshi-Li Biotech, Mainz, NJ). Concanavalin A (Con A) was obtained from Sigma (St Louis, MO). Polyclonal SEA, SEB and TSST-1 were obtained from toxin technology (Bioscience, PL-3, 6–4) was produced in methicillin-resistant amplified Chinese hamster ovary cells and was a kind gift from Dr M. From (Ghent University, Ghent, Belgium).

Cell lines

The 1A2F1-restricted, myoglobin-specific T cell hybridoma 15-50-4-F5 (1A2) was derived by Dr A. Langhorne (Institute Institute of Immunology Basel, Switzerland).

The 1A2F1 gene was introduced into the pA201 cell lymphoma cell line (described through the ATCC, Rockville, MD) by electroporation. Poly-A⁺ RNA was isolated from the 1A2F1 cell line (1T) using the Quickspin mRNA RNeasy purification kit from Pharmacia (Laplace, Sweden). First strand cDNA was made using an oligo(dT) primer and the superscript pre-mix (Gibco-BRL, Gaithersburg, MD, USA) Life Technologies, Merelbeke, Belgium. Amplification was performed in a 50 µl volume containing 10 pmol 1T, pH 8.2, 50 mmol KCl, 2 mmol MgCl₂, 0.01% (w/v) gelatin, 30 pmol of each oligo-nucleotide primer, 600 µmol of each deoxynucleotide triphosphate and 1.25 U Taq polymerase (Calco, Emmenloot, CA) in 1.0 µl of the first strand cDNA reaction mixture. The primers spanning the start and stop codons of the B7 sequence used were the sense primer, 5'-GTCAAGGCTGTCTAAGCAGAGGCTGGAGT-3', and the antisense primer, 5'-GGCCGCTCTGCTTAACTGTCTCTCAAGGAGC-3'. Each PCR cycle consisted of 94°C heat denaturation for 0.5 min and primer annealing at 58°C for 0.5 min followed by primer extension at 72°C for 1 min. Forty cycles were performed in a heated thermocycler (Bio-Rad, Brussels, Belgium). The 1A2F1 polymerase chain reaction (PCR) product of 160 bp was purified and cloned into the pUC19 vector of the bacterial vector pAMP/CMV-16 kindly provided by Dr R. Balazs (Ghent, Emmenloot, CA) and sequenced using Sbf1 restriction (restriction sequencing) procedures with ³²P-labelled primer and Sequencer (Amersham Pharmacia Biotech, Oriskany, NY). Clones with correct sequence were also for transfection of the packaging cell line Y2, using a liposome transfection kit (Lipofectamine 2000, Gibco-BRL, Gaithersburg, MD, USA). After 48 h the cells were transferred on culture medium containing 2 mg/ml gentamicin (G418 sulfate (G418 SR)) (Sigma) clones were tested for B7 expression by staining with CTLA-4-Ig. High level clones were selected by subsequent infection of 293A293 cells. 293 cells were infected by co-culture of a 10:1 ratio in the presence of 0.5 µg/ml polybrene during 48 h. The cells were gently removed from the medium and subcloned in culture medium containing 1 mg/ml gentamicin G418. Surviving clones were tested for B7 expression by FACS analysis.

Flow cytometry

Cells were analysed by flow cytometry with a FACScan cytometer (Becton Dickinson, Mountain View, CA). PE-Cy5.5-IL-4-IL-2 (mouse anti-IL-2⁺, available through the ATCC) and anti-CD8 (mAb 1B6-2C11 anti-CD8) [31] were purified and modified in our laboratory according to standard procedures.

The FITC-coupled anti-mouse CD8, phycoerythrin (PE)-coupled anti-mouse α and PE-coupled anti-mouse CD4 were purchased from Becton-Dickinson (Ornat, CA). In all cases, cells were gated according to size and scatter in order to eliminate dead cells and debris from analysis.

In vitro responses

Spleen cell suspensions were depleted of adherent cells by passage over Sephadex G15 (Pharmacia) columns as described [18]. Spleen T cells were purified following G15 passage and removal of $\alpha\beta^+$ cells by MagnaCell Sorter (MillicellBiosciences, Bedford-Stadford, Germany). The resulting population contained $\sim 1\%$ $\alpha\beta^+$ or $\alpha\gamma^+$ cells and comprised 10–80% of CD3⁺ cells.

APC were obtained following complement-mediated lysis of normal spleen cells produced in our laboratory according to standard procedures of anti-Thy-1.2 (clone 1A2-10-48, available through the ABCD) labelled spleen cells or G15-passed spleen cells. The resulting population contained $\sim 1\%$ CD3⁺ cells. Spleen DC were purified as previously described [20] and contained $\sim 95\%$ of MHC II^+ [anti-CD11c cells (P14) cells and no detectable levels of CD3⁺ or $\alpha\beta^+$ cells ($<1\%$). Peritoneal macrophages were purified from available cells obtained following extensive washing of the peritoneal cavity with CD4561 sucrose buffer at 4°C. After overnight culture in FCS-containing media, non-adherent cells were discarded and adherent cells were collected by scraping with a plastic rubber policeman. The resulting population contained at least 80% of macrophages, as assessed by morphology and specific staining using MHC-I mAb (APC).

All *in vitro* immune responses were performed in serum-free media containing 4000–1600 (GibcoBRL, Gaithersburg, MD, USA) supplemented with 7% FCS (GibcoBRL, Gaithersburg, MD, USA), non-essential amino acids, sodium pyruvate, 2-mercaptoethanol and L-glutamine (Flow CH Biomedicals, Basingstoke, UK).

An adequate number of responder and stimulator cells (see Results for cell numbers) are stimulated by soluble mAb or superantigens in a total volume of 0.2 ml in 96-well U-bottom plates. Cultures were maintained at 37°C in a humidified incubator (7% CO₂). Supernatants were collected after 18–24 h of culture, frozen and passed by a 0.2 μm filter using a standard bioassay using a subclone of the CTL cell line responsive to murine IL-2 [21]. Proliferation of this cell line induced by supernatant from stimulated T cell cultures is completely inhibitable by the anti-mouse IL-2 mAb 3A88. Standard curves were generated using human IL-2 and results expressed as LRF or U/L. If any test point failed to two-way ELISA using mAb F1 and 2a11, kindly provided by Dr Willem Frits, Leuven, Belgium and P. H. Van Der Made (TNO Health Research, Rijswijk, The Netherlands) respectively.

Results

*Role of co-stimulation in the *in vitro* immune response of splenic T cells to SEB*

The present study was undertaken in order to investigate the role of co-stimulation provided by accessory cells for the

in vitro response of splenic T cells to bacterial superantigens. It has been previously established that removal of Sephadex G15-adherent cells from the splenic APC population abrogated the ability of these cells to stimulate an *in vitro* primary thymocyte response [22]. Since percentages of B ($\alpha\beta^+$) and T ($\text{Thy}1^+$) cells are not appreciably altered by passage over G15 columns [19] and our own observations, it is assumed that APC able to induce primary *in vitro* mixed lymphocyte reaction mostly comprise G15-adherent cells such as macrophages and/or DC. This observation supported us in that case, if leaving B cells, although able to present and present antigen [24], were unable to provide the co-stimulatory signals required for the activation of resting T cells. In order to test this hypothesis, we included in our analysis a thymocyte-specific, $\alpha\gamma$ -bearing T cell hybridoma, as numerous studies have suggested that T cell hybridomas responded optimally to TCR ligands in the absence of co-stimulatory ligands provided by APC [25–28] and this study. We therefore assumed that the capacity of selected APC populations to generate the adequate TCR ligand could be monitored by their ability to stimulate a T cell hybridoma.

As a first approach, we compared the accessory cell function of unactivated or G15-passed purified splenic APC labelled following complement-mediated lysis of $\text{Thy}1$ -bearing spleen cells. Purified splenic T cells were stimulated by SEB (5.0 $\mu\text{g/ml}$) in the presence of selected APC populations and IL-2 production was assayed following overnight culture. Figure 1 indicates that unactivated splenic



Fig. 1. Comparison of accessory cell function of splenic and G15-passed splenic APC. The 10–10–5–10⁵ T cell hybridoma is used as the $\text{Thy}1^+$ indicator and purified splenic splenic T cells ($\alpha\gamma$ T cell) are used as the responder. Splenic APC (5.0 $\mu\text{g/ml}$) are used (see legend) (100%) to give greatest amount $\text{Thy}1^+$ splenic cells (APC, 10⁵ or 10⁴), 10-fold dilution of APC (10⁵ or 10⁴) or unactivated splenic cells (unactivated APC, 10⁵ or 10⁴) are indicated. Culture supernatants were assayed by IL-2 bioassay bioassay and results are expressed as LRF.




Fig. 4. (a and b) Comparison of accessory cell function of selected APC populations. Response of T cells has legend as Fig. 1 for details. Experimented with B6H-2D^b (gag) and selected APC populations including (Fig. 1) splenic cells (APC+SC), Thy-1⁺ 2D^b-positive splenic cells (APC+SC+GIR⁺), purified splenic DC and purified PBC. All APC populations were cultured for 5 h in complete media for media containing IL-2 when indicated. After 24 h, culture supernatants were assayed for IL-2 content. In summary, our results are reported as (a) (a) IL-2 cell surface expression on selected APC populations. The indicated APC populations were stained with FITC-labeled anti-CD45⁺ anti-CD45⁺ and a specific anti-CD45⁺ monoclonal antibody. All staining was performed under conditions of saturating doses of APC, a technique to maximize IL-2 in order to select full-length of staining reagents.

APC efficiently presented SEB to both splenic T cells and T cell hybridoma. No IL-2 production was obtained when T cells or SEB were omitted from the culture (data not shown). Removal of *Staphylococcus*-adherent cells from the splenic APC population did not significantly modify the ability of these cells to present SEB or antigen (unpublished) to a T cell hybridoma (Fig. 1a and b). In marked contrast, the G₁-passaged APC fraction was unable to induce IL-2 production from splenic T cells in the presence of 0.1 µg/ml of SEB. In the light of the two-signal theory of T cell activation, these data suggest that G₁-passaged APC were able to process antigen and generate an appropriate TCR ligand since they correctly presented SEB and antigen to a T cell hybridoma, but failed to deliver the required co-stimulatory signals to naive T cells in this culture conditions. Like that normal antigen-presenting cells (APC) represent a better stimulus for a naive T cell hybridoma (SEB) (compared to Fig. 1a and b), an observation that probably relates to the finding that SEB binds with low affinity (forming class II molecules) [26]. Accordingly, several reports demonstrated that bacterial superantigens display a higher affinity for human class II proteins than for murine IL

antigens and that murine T cell hybrids are optimally stimulated by superantigens presented by human APC.

In order to identify the antigen-cell population(s) able to reduce the response of naive T cells to SEB, splenic T cells were stimulated in the presence of purified splenic DC known to represent APC for naive T cells [1,2,27,28] (antigen-presenting cells (APC)). T cells were also stimulated in the presence of unfractionated (and G₁-passaged) APC, obtained as previously described. Of note, the purification procedure of DC required an overnight culture step during which co-stimulatory activity appears to be up-regulated [1,28,29] and M. Hesse, in preparation. All APC populations were therefore cultured overnight in complete media or, when indicated, in media supplemented with recombinant murine IL-4. By comparing the response of naive T cells and of a T cell hybridoma, we were able to equal the ability of selected APC populations to generate a TCR ligand (signal 1) and/or deliver the adequate co-stimulatory signal(s) (signal 2) to naive T cells. The results presented in Fig. 2 can be summarized as follows. The ability of APC to deliver signal 1 strongly correlated with the cell surface expression of the IL-2 molecule, known to bind and




Fig. 3. Role of Q12-adherent APC populations in naive T cell responsiveness to superantigens. B6B, B6A and B6B.4 (B6B.4, B6B.4.1 or B6B.4.2) responder spleen cells (CD4⁺CD25⁺ cells) cultured in the presence of a graded dose of bacterial superantigens or T cell mitogens as indicated. Culture supernatants were assayed for IL-2 content by bioassay. Results are expressed as (pg/ml) of 125 I-labelled concanavalin A in the IL-2-dependent cell line Q12.

present B6B, DC expressed high levels of class II molecules and were indeed very potent stimulators of the T cell hybrid, according to up-regulation of IL-2 cell surface expression. Interactions by L-4 with B6 cells resulted in a 10-fold increase in the ability of these cells to stimulate the T cell line. In contrast, B6C, which expressed low levels of IL-2 molecules in the absence of external stimuli, were unable to present Q12 in culture to the T cell hybridoma.

Among cells able to present B6B to the T cell hybridoma, only purified B6 (Fig. 3b, c) doses required and unfractionated spleen APC (Fig. 3d, e) concentrations were found to significantly induce IL-2 production from naive T cells. In particular, B cells cultured in the presence of L-4 were only weak stimulators for naive T cells in spite of high levels of cell surface IL-2 expression (Fig. 3f). Data presented in Fig. 2 suggest therefore that although DC and L-4 treated B cells express similar levels of cell surface-associated IL-2 molecules and are able to optimally stimulate a T cell hybridoma, they display distinct co-stimulatory activity for naive T cells.

Response of unfractionated and Q12-passed responder cell populations to greater doses of superantigens and T cell mitogens

In order to establish whether activation of naive T cells was strictly dependent on the co-stimulatory activity provided by




Fig. 4. Q12-passed spleen cells are strictly required for IL-2 production in response to all doses of T cell mitogens tested. For experimental conditions, see caption Fig. 3. Supernatants collected after 24 h in culture were assayed for IL-2 content by bioassay and the results expressed as (pg/ml).

adherent accessory cells, B6-passed spleen cells were stimulated by increasing doses of superantigens and T cell mitogens. Dose-response curves obtained with different superantigens and mitogens are shown in Fig. 5. Q12-passed spleen cells (containing both Th1⁺ and Th2⁺ cells) were able to mount an in vitro T cell response to superantigens but required higher doses of superantigens for detectable IL-2 production. In contrast, removal of adherent cells from the responding population did not significantly affect their response to Con A or anti-CD3/anti-IL-2, indicating thus that the different threshold of activation observed with superantigens was not due to a genetically determined hypersensitivity of the responding T cell population present in the B6-passed fraction.

As previously reported by others (28), we have observed that although Q12⁺ T cell reacts with a small subpopulation of naive T cells, it induces high levels of IL-2 production *in vitro* (see Fig. 3b). Note also that IL-2 production in the Q12-passed population induced by saturating doses of superantigen generally exceeds the response of the unfractionated population. Although further studies (including precursor frequency analysis and sorting experiments using antibodies to CD44) are needed to elucidate this observation, flow cytometric analysis suggest that the Q12 population is enriched for small resting T cells, a cell population that has been shown to be hypersensitive to superantigens *in vivo* (29).

In contrast to what was observed for IL-2 production,

distortion of adherent cells from the responding population completely abrogated the IFN γ response induced by an antigen feeder (Fig. 4). IFN γ secretion was fully restored by addition of unactivated splenic APC or purified DC to a 5:100:100 responder cell population (data not shown). This observation suggests a functional heterogeneity among splenic APC. IL-2 production can be induced by both adherent and non-adherent APC, while IFN γ production is only observed in the presence of adherent splenic cells.

Anti-CD28 mAb, DC and BT-1 bearing *in vitro* mature IL-2-producing *in vitro* T cell culture supernatants of superantigens. The previous observation suggested that co-stimulatory activity provided by adherent splenic cells modulated the *in vitro* IL-2 production of naive T cells by lowering the threshold of activation to superantigens. Since antibodies to CD28 have been shown to provide a co-stimulatory stimulus to naive T cells [14], we tested whether they were able to rescue the sensitivity of 5:100:100 responder cells to control levels. Figure 5 shows that addition of anti-CD28 mAb upregulated the response of 5:100:100 splenic cells to superantigens by lowering the threshold of activation and increasing the total amount of IL-2 produced at plateau levels. Following a similar rationale, we wished to test whether the addition of purified DC was also able to modify the *in vitro* response of naive T cells to superantigens. Figure 6 shows that addition of DC cells to 5:100:100 splenic cells augmented their *in vitro* response to superantigens by both lowering the threshold of activation and increasing the production of IL-2 production. As shown before, a similar result was obtained by supplementing the culture with antibodies to anti-CD28. In order to test the ability of one of the recently identified CD28 ligands to provide a co-stimulatory stimulus to GIL-passed responder cells, we tested the ability of a BT-1-transfected cell line to present SEB and Q2A-passed responder cell populations. A stable cell line expressing high levels of the murine BT-1 molecule (A20-BT-1) was produced following transfection of the corresponding gene. As shown in Fig. 7, the parental cell and the transfected cell line displayed equivalent amounts of cell surface H-2 molecules while expressing different levels of the BT-1 molecule. In agreement with data presented in the previous sections, CD28 cell lines were equally effective in stimulating the V β 1-bearing T cell lymphoma in the presence of SEB or Q2A (Fig. 8a and b), thus confirming that the lymphoma is insensitive to BT-1-mediated co-stimulation. In contrast, the BT-1-transfected cell line proved to be more effective in presenting superantigens to Q2A-passed cell populations (Fig. 8a and b), indicating that this experiment was performed using donor cell densities (10⁵ responder cells/ml). In order to favor antigen presentation by the A20 cell line, BT-1-mediated co-stimulation affected the *in vitro* immune response by increasing the sensitivity of unprimed T cells to lower doses of SEB and Q2A. Of note, the *in vitro* response of T cells to anti-CD28 antibodies and feeder cell was sensitive to BT-1-mediated co-stimulation, although to a lesser extent.

Discussion

An important feature of superantigens is the fact that they do not undergo processing but directly engage MHC class II




Fig. 4. Co-stimulatory effect of naive to CD28. Unactivated (5:100) or 5:100:100 (5:100) splenic cells were stimulated by graded doses of bacterial superantigens and antibodies to CD28 (from 10⁻⁷ to 10⁻¹ concentration) alone (SEB). Both antibodies were used at 1:10000 dilution in solution. After 24 h, culture supernatants were assayed for IL-2 content by bioassay. Results are expressed as C.P.M. of [³H]-thymidine incorporation by the IL-2-dependent cell line C2B4.

molecules on the APC and subsequently bind to T_H receptors of the TCR/CD4 complex [1]. No superantigen-induced require APC capture and internalization, they can potentially bind to all class II⁺ cells *in vivo*. In contrast to classical antigens which appear to be preferentially captured and presented to T lymphocytes by APC of the DC lineage (DC), the focus of the experiments reported herein was to compare the ability of unsorted APC populations to stimulate naive T cells in the presence of bacterial exotoxins.




Fig. 8. Dose-response effect of purified DC and antigenic O-220B cells on IL-2 production. DC (500) or antigenic cells (10⁴ cells/ml) were stimulated for greatest doses of bacterial superantigens in the presence of responder cells (2000 cells/10⁴ cells) in 96-well culture medium. Antigenic peptide (10⁴ ng/ml) (BSB) or antigenic peptide (10⁴ ng/ml) (SEA) or antigenic peptide (10⁴ ng/ml) (TST-1) were added to the culture medium. DC (500) cells/ml, antigenic cells (10⁴ cells/ml) were added to the culture medium. IL-2 production was measured after 24 h. Culture supernatants were collected for IL-2 containing medium and results are expressed as pg/ml.

Purified DC were found much more efficient on a per cell basis than testing in IL-4-treated B-cells in stimulating naive T cells to produce IL-2 in the presence of BSB, in spite of similar MHC surface expression and comparable activating properties when presenting superantigen to a T cell hybrid (see experiments performed with IL-4 treated B-cells, Fig. 2). This result indicates that, in contrast to what has been previously suggested by Mouton *et al.* [35], high efficiency of DC in presenting BSB to naive T cells relates to the




Fig. 9. FACS analysis of surface ADR expression. Isolated ADR cell lines. Cell surface antigen expression was assessed by incubating isolated TCR-bearing splenocytes with BSA or B1.1 (a). An example was performed in the presence of blocking doses of anti-ADR mAb to ensure FACS, in order to allow full binding of staining reagents.

presence of co-stimulatory activity rather than to the higher amounts of MHC-superantigen complexes that they present. Removal of adherent cells from the responding population did not completely abrogate IL-2 response to superantigens, but rather reduced sensitivity of naive T cells to lower doses of superantigens. Reduced IL-2 secretion was not observed in response to anti-CD3/anti-IL-2, suggesting that BSA passage did not significantly affect T cell responsiveness to TCR cross-linking. CD3-passed splenic cells failed to produce detectable levels of IFN- γ in response to superantigens, and CD8 cells and naive, confirming previous work from Rottengruber *et al.* [32], who showed that adherent cells were required for superantigen-induced IFN- γ secretion. IFN- γ production was restored by addition of T cell depleted spleen cells or enriched DC to the 24 h-potent responding population, demonstrating that lack of IFN- γ response was solely attributable to an APC defect (data not shown). Pulse fraction complete isolation of IFN- γ -producing TCR⁺ culture demonstrates that residual IL-2 response induced by superantigens cannot be attributed to adherent cells containing the CD3-passed responding population. The nature of co-stimulatory activity provided by adherent spleen cells for IL-2 production is not entirely clear as it may comprise both secreted molecules as well as membrane associated factors. Reconstitution




Fig. 6. Co-stimulatory activity of the CD8-3T1-transfected cell line. The CD8-3T1 T cell hybridoma (a and b, *Staphylococcus aureus* SEA) or CD8-3T1 T cell hybridoma (c and d, *Staphylococcus aureus* SEB) were stimulated by graded doses of superantigens or T cell antigens in the presence of CD8 or ST1-transfected cell lines (e and f). Subsequently, after 24 h, culture supernatants were assayed for IL-2 content by bioassay and results are expressed as U/ml.

experiments using antibodies to CD85, ST1-transfected cell lines or CD8-expressing ST1 and ST2 molecules (see 3D and our own observations) indicated that co-stimulatory activity provided by the CD85-CD134 receptors increased T cell responsiveness to limiting doses of superantigen and resulted in sustained levels of IL-2 production at saturating doses of superantigen. Increased (plateau) levels of IL-2 production are in agreement with observations indicating that signals transmitted through CD85 cluster is matched (as in cytokine receptor stability [26]). Of note, these experiments were not designed in order to identify the nature of co-stimulatory factors provided by adherent cells, but rather to confirm that APC products derived from the MHC-superantigen complex can decrease the superantigen threshold of naive T cells for IL-2 production.

This study clearly demonstrates that the APC population able to activate naive T cells in response to superantigens is heterogeneous. Both adherent (comprising DC) and macrophages and non-adherent APC (mostly B cells) have been shown to induce naive T cell proliferation, with different efficacy. Although co-stimulation productivity adherent spleen cells (in particular DC) increases T cell reactivity to superantigens, it may not represent an obligatory signal for IL-2

production in response to superantigens. As demonstrated in this work, the co-stimulation requirement is a function of superantigen concentration and high doses of superantigen (in the μ g/ml range) may obscure the contributions of APC-derived co-stimulatory factors. Note, however, that no stimulation provided by adherent spleen cells, and particularly DC, appears to be required for IFN- γ secretion induced by all antigens tested.

The hypothesis that underlies some of the conflicting observations reported in the literature. Thus, although in both murine and human model systems, CD85-3T1 receptors have been demonstrated to be necessary for effective activation by conventional (SE) or *abc*-(SE) antigens, it is not clear whether activation by superantigens is strictly dependent upon signaling through CD85-CD134 receptors. Inhibition of CD134-4 has been shown to have no effect on the activation of IL-2-induced by superantigens presented to human naive T cells by an Epstein-Barr virus-transformed B cell [18] while antibodies to CD85 inhibit human T cell activation mediated by superantigens presented by DC [33]. In another study, CD134-4-blocked (SEB-induced) murine T cell proliferation [38], regardless of the type of APC delivering the activation signal. Differences observed in blocking studies may relate to species and superantigens used (SEA and SEB display a higher affinity for human than for murine MHC molecules) and experimental conditions (response to purified superantigen versus soluble superantigens). Moreover, these studies do not resolve whether blocking was due to interference with adhesion or with co-stimulatory activity. In contrast, use of ST-transfected cells or APC naturally expressing high levels of ST-related molecules that constitutively distributed at higher efficacy of superantigen presentation from 10⁻⁸ to 10⁻⁶ fold by APC expressing co-stimulatory activity, compatible with the hypothesis that CD85-CD134 co-stimulatory plays a similar role in antigen- and superantigen-mediated activation [37]. To exploit these observations, we consider that the ability of a naive T cell to respond to a given stimulus is a function of TCR affinity, density of TCR-specific ligands and expression of co-stimulatory activity. The simplest form of this hypothesis would predict that the molecular complex formed by antigen, class II and TCR elements (as noted that is commonly referred to as 'signal 1') is usually itself sufficient to initiate T cell activation under certain experimental conditions. An TCR antibodies, presumably, displays a higher affinity for TCR than natural antigen-MHC ligands and can be used at high cell concentrations. As a consequence, naive T cells can be stimulated in the absence of cells delivering signals to peptide-bound anti-CD3 mAb or when cultured at high cell densities [39]. Although total absence of APC is difficult to prove, these studies suggest that activation of naive T cells by antibodies to the TCR complex may occur independently of CD85-derived signals. Bacterial exposure (presumably tied to an associated set on the MHC molecule and recent studies in a human model [37] have demonstrated that 100% of MHC class II⁺ molecules occupancy is altered at 10 mM dose of SEA (corresponding to a working concentration of 1-5 μ g/ml). Sufficient TCR cross-linking might therefore be induced at high superantigen doses, rendering co-stimulatory productivity irrelevant or dispensable. This observation does not negate the possibility that other co-stimulatory

molecules expressed by host lymphoid cells (such as CD71 or CD83) play a role in B cell-mediated stimulation of naive T cell in the presence of high concentrations of superantigens. In most contexts, stimulation of T cells by peptide antigens is limited by the presence of naturally processed peptide which binds to MHC molecules on APCs. It has been estimated that even when added at saturating doses, only 0.1–1.5% of total MHC molecules are occupied by a given antigenic peptide [40]. Thus, under physiological situations, antigen stimulation of T cells appears strictly dependent on co-stimulatory factors provided by APC, an 'signal 1' provided by antigen-MHC complexes, a presumably weak function activation. Accordingly, Q15-passed APC do not stimulate unresponsive T cell CD3 and/or CD4-dependent co-stimulatory rates T cells to produce IL-2 in the presence of adequate concentrations of superantigens. Of interest, a recent study performed by C. Mudd and colleagues demonstrated that DC and the antigen presenting dendritic mature line P815.12 require only APC able to induce primary cytotoxic T lymphocyte responses (P815, P815-2 cells display a reduced and surface-expressed MHC class I molecules which properly be rescued by addition of MHC class I binding peptides. The results indicated expression of MHC class I molecules preferentially loaded with major histocompatibility peptide, presumably because in competition with naturally processed self peptides occurred in this mature cell line. Of relevance, the non-stimulated, parental P815 culture was unable to induce primary or *in vivo* responses suggesting that increased expression of other antigen-MHC complexes conferred to the mature cell line the ability to stimulate naive T cells. Taken together, these observations suggest that co-stimulatory molecules play a predominant role in T cell activation when T cells are stimulated by the highly TCR ligands.

One conclusion that clearly follows from this study is that superantigens can be presented to naive T cells by cells expressing different co-stimulatory activities. By binding with high affinity to an unoccupied site on the MHC class II molecule, bacterial exotoxins bypass physiological requirements for antigen capture and processing, and are able to generate significantly ligands able to efficiently cross-react TCR even after presented by cells bearing weak co-stimulatory activity. This is particularly relevant as superantigens have been shown to both potently activate naive T cell in vivo (using both intravenous and intracutaneous administration) and induce anergy with clonal stimulation [41]. Unexplained, *in vivo* pathophysiological effects of superantigens may therefore require the identification of the cells presenting superantigens to naive T cell in vivo as numerous studies (for review, see [2]) have suggested that functional co-localization of TCR occupancy (primary signal) is determined by co-stimulatory signals provided by APC.

Acknowledgements

The authors wish to thank A. Riquelme and S. Crespo for expert technical assistance. Drs J. Wilson, B. Park, A. Compston, M. Wilson, A. Whittall and P. H. are the British biotechnology superantigen research support unit. We thank for helpful discussions. The work was financially supported by the Spanish Program in Immunology (Plan of Science and Technology for the Basque Region, PIRE-1994) and the Basque Government. The authors

responsibility is assumed by its authors. S. M. is supported by a grant from the PIRE, M. M. and G. L. are Research Associates from the Spanish Ministry of Scientific Research and Technology.

Abbreviations

APC	antigen presenting cell
CD3 & CD4	cell-surface T cell receptor
CD4	co-receptor
CD8	co-receptor
CD28	co-stimulatory receptor
CD45	leukocyte common antigen
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45RI	intermediate T cell marker
CD45RJ	intermediate T cell marker
CD45RK	intermediate T cell marker
CD45RL	intermediate T cell marker
CD45RM	intermediate T cell marker
CD45RN	intermediate T cell marker
CD45RO	memory T cell marker
CD45RA	naive T cell marker
CD45RB	intermediate T cell marker
CD45RC	intermediate T cell marker
CD45RD	intermediate T cell marker
CD45RE	intermediate T cell marker
CD45RF	intermediate T cell marker
CD45RG	intermediate T cell marker
CD45RH	intermediate T cell marker
CD45	

66. Sakai, S., Salina, R. A., Hsi, C. S., Carnahan, R. H., Peterson, C. B. and Longmire, W. 1990. Presentation of antigen by class II major histocompatibility complex (MHC) class II gene products in normal T cells. *J. Exp. Med.* **171**, 181.
67. Kaul, S. and Saitoh, A. 1988. Spontaneous murine B-cell leukemia. *Leuk.* **17**, 120.
68. Liu, Y., Pitt, M., Huetten, G., Janszani, L. B. and Blumberg, P. M. 1989. Identification of monoclonal antibody specific for a murine T-cell line. *Proc. Natl Acad. Sci. USA* **86**, 5653.
69. Kaul, S., Li, J., Singer, A. and Saitoh, A. J. 1983. Heterogeneity of murine T cell clones. In *Immunology*, Pt 2, Miller, P. L., Sakai, S. A. and Saitoh, A., eds. *Annual of Microbiology, Immunology, Immunology, Immunization and Function*, p. 107. Marcel Dekker, New York.
70. Schmitt, T., Hagedorn, P., de Boer, J. A., Boes, M., Tackmann, P., Schneider, K., Green, J., Lee, G. and Biele, H. 1989. Antigen-presented dendritic cells can efficiently induce an antibody response in vivo. *J. Exp. Med.* **170**, 1515.
71. Miller, J. P., Wilson-Pick, M. B., Appel, R., Crowley, M. T., Lachman, S. and Saitoh, A. 1988. The murine leukocyte antigen of mouse spleen dendritic cells is identified with two murine monoclonal antibodies. *J. Exp. Med.* **171**, 1753.
72. Miller, P. and Tachibana, P. 1989. A T cell clone which responds to dendritic T but not to Interleukin-1. *Eur. J. Immunol.* **17**, 559.
73. Singer, A., Kaul, S., Li, J. M. and Imbrighi, P. A. T. 1984. Cell-to-cell interactions: cell to cell (cellular) cellular T lymphocytes, dendritic cells, and cells to dendritic cells and to dendritic cells. *Immunol. Cell. Immunol.* **10**, 100.
74. Singer, A., Li, J. M. and Imbrighi, P. A. T. 1984. Antigen presentation by resting T cells. Identification of resting T cell proliferation is determined by dendritic antigen, not T cell receptor molecules. *J. Immunol.* **133**, 588.
75. Mayhew, S. and Saitoh, A. 1988. T12-12 molecules isolated from B6H mice induce cells to rest (cells) to respond to T cell dendritic antigen. *Immunol. Cell. Immunol.* **14**, 100.
76. Saitoh, A., Saitoh, S., Saitoh, A. P., Saitoh, J. and Saitoh, P. 1989. HLA-DR when after a few days, a small number of dendritic cells. *J. Exp. Med.* **170**, 1515.
77. Saitoh, A. 1989. The dendritic cell system and its role in immunoregulation. *Ann. Rev. Immunol.* **7**, 125.
78. Miller, J. P., Crowe, K., Hall, C., Wang, K. and Saitoh, A. 1988. Phenotypic and functional properties of T cell dendritic cells derived from the superantigen T12-12. *Eur. J. Immunol.* **17**, 1549.
79. Lee, G. T., Smith, J. S. 1989. Memory T cell activation by the superantigen T12-12. *Eur. J. Immunol.* **17**, 1555.
80. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
81. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
82. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
83. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
84. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
85. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
86. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
87. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
88. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
89. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
90. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
91. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
92. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
93. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
94. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
95. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
96. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
97. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
98. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
99. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.
100. Saitoh, A., Saitoh, S. and Saitoh, A. 1988. Dendritic cells are the primary cells to induce antigen-specific T cell responses. *J. Exp. Med.* **170**, 1515.

Received 10 October 1990; accepted 10 November 1990

Correspondence: Dr A. Saitoh.

Dr A. Saitoh, Department of Immunology, University of

Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan.

© 1991 Blackwell Science Ltd

Printed in the United Kingdom

0950-2688/91 \$05.00

Journal of Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334

Immunology, 1991, 146, 324-334